Skip to main content
Xvivo Perfusion logo

Xvivo Perfusion — Investor Relations & Filings

Ticker · XVIVO ISIN · SE0004840718 LEI · 549300G2464FYLS14B41 ST Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2021-03-29 Annual Report (ESEF)
Country SE Sweden
Listing ST XVIVO

About Xvivo Perfusion

https://www.xvivogroup.com/

Xvivo Perfusion is a medical technology company specializing in ex-vivo organ preservation for transplantation. The company develops machine perfusion technologies, solutions, and services designed to extend the life of major organs, including lungs, livers, and kidneys. Its core technology, organ perfusion, is an alternative to static cold storage that continuously supplies an organ with an oxygenated solution while it is outside the body. This process helps support cellular function, prevent tissue damage, and allows clinicians to assess organ viability prior to transplant. The company's objective is to increase organ utilization, extend preservation times, and improve patient outcomes. Key products include the XPS™ for lung perfusion, Liver Assist™, Kidney Assist Transport™, and the PERFADEX® Plus solution for lung preservation.

Recent filings

Filing Released Lang Actions
Annual Report (ESEF) 2020
Annual Report (ESEF) Classification · 100% confidence FY 2020
2021-03-29 English
Notice to attend the Annual General Meeting in XVIVO Perfusion AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled "Notice to attend the Annual General Meeting in XVIVO Perfusion AB (publ)" and details the date, time, location, procedures for notification, advance voting, proxy submission, and the proposed agenda for the meeting. The agenda items cover the election of the Chairman, approval of minutes, financial reports submission, remuneration reports, and resolutions regarding remuneration guidelines and share issues. This content is characteristic of materials distributed to shareholders in preparation for an Annual General Meeting (AGM). While it mentions the submission of the annual report (Item 7), the document itself is the notice and associated proposals, making 'AGM Information' (AGM-R) the most appropriate classification, as it directly relates to the meeting logistics and proposals.
2021-03-15 English
Kallelse till årsstämma i XVIVO Perfusion AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled "Kallelse till årsstämma i XVIVO Perfusion AB (publ)" which translates to 'Notice of Annual General Meeting' in Swedish. It details the date, time, location, procedures for participation (including advance voting due to COVID-19 precautions), and presents the proposed agenda items for the meeting. The agenda includes items typical for an AGM, such as electing the chairman, approving the annual report (Item 7), decisions on profit distribution (Item 8b), approving the remuneration report (Item 12), setting remuneration guidelines (Item 13), and proposing changes to the articles of association (Item 14). This content perfectly matches the definition of materials shared during an Annual General Meeting. Although it contains remuneration details (DEF 14A content) and mentions the annual report (10-K content), the primary purpose and structure of the document is the formal summons and agenda for the AGM. Therefore, the most accurate classification is AGM Information (AGM-R).
2021-03-15 Swedish
Earnings Release 2020
Earnings Release Classification · 99% confidence The document is titled "BOKSLUTSKOMMUNIKÉ 2020" (Year-End Report 2020) and contains detailed financial information for the Fourth Quarter 2020 and the full year 2020 (JAN – DEC). It includes key financial metrics like sales, EBITDA, EBIT, net result, cash flow, and significant business events related to the full fiscal year. This structure—presenting detailed financial results for the full year and the final quarter—is characteristic of an Annual Report or a comprehensive year-end financial disclosure. Given the depth of the financial review and the year-end focus, it aligns best with the scope of an Annual Report (10-K), although it is presented in Swedish and might be a local equivalent. Since the text provides the full financial performance summary for the year, it is classified as the primary annual financial document. Q4 2020
2021-01-28 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report titled 'REPORT ON OPERATIONS 2020' for XVIVO Perfusion AB. It contains detailed financial statements, including income statements, cash flow analysis, and segment reporting for both the fourth quarter and the full year 2020. It also includes management commentary (CEO's comments), operational highlights, and significant events. Since it covers a period shorter than a full fiscal year (Q4) and provides substantive financial data and analysis, it is classified as an Interim/Quarterly Report. FY 2020
2021-01-28 English
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document details a change in shareholding percentage for a specific instrument (Aktier SE0004840718) by a holder (Swedbank Robur Fonder AB) in an issuer (Xvivo Perfusion Aktiebolag). It explicitly shows the 'Before the transaction' and 'After the transaction' share counts and resulting percentages (crossing the 10% threshold). This type of filing, reporting changes in significant share ownership, directly corresponds to the Major Shareholding Notification category.
2020-12-01 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.